Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,290,460
  • Shares Outstanding, K 62,492
  • Annual Sales, $ 0 K
  • Annual Income, $ -210,750 K
  • 60-Month Beta -0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.90
  • Number of Estimates 6
  • High Estimate -0.84
  • Low Estimate -1.00
  • Prior Year -0.91
  • Growth Rate Est. (year over year) +1.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.25 +4.47%
on 05/06/19
22.15 -9.19%
on 05/16/19
-0.29 (-1.42%)
since 04/17/19
3-Month
19.25 +4.47%
on 05/06/19
25.81 -22.08%
on 03/04/19
-4.10 (-16.94%)
since 02/15/19
52-Week
19.25 +4.47%
on 05/06/19
36.12 -44.32%
on 11/07/18
-9.90 (-32.99%)
since 05/17/18

Most Recent Stories

More News
Aimmune to Present at RBC Capital Markets Global Healthcare Conference

Aimmune Therapeutics, Inc.(Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt,...

AIMT : 20.11 (-2.62%)
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S. Food...

AIMT : 20.11 (-2.62%)
Watch for Aimmune Therapeu to Potentially Pullback After Gaining 4.45% Yesterday

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $20.22 to a high of $21.02. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high...

AIMT : 20.11 (-2.62%)
Aimmune Therapeutics: 1Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Wednesday reported a loss of $54.3 million in its first quarter.

AIMT : 20.11 (-2.62%)
Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights

--Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial

AIMT : 20.11 (-2.62%)
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday,...

AIMT : 20.11 (-2.62%)
Global Peanut Allergy Market Report 2019: Insights, Epidemiology and Market Forecasts 2017-2028 Featuring Aimmune Therapeutics, DBV Technologies, AnaptysBio, & Genentech

The "Peanut Allergy - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

AIMT : 20.11 (-2.62%)
Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference

Aimmune Therapeutics, Inc.(Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., President and Chief...

AIMT : 20.11 (-2.62%)
Shares of Chemocentryx Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (CCXI , VCYT , AIMT , MGNX , MRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 24.39 (-2.87%)
AIMT : 20.11 (-2.62%)
MRTX : 73.91 (+4.73%)
CCXI : 12.43 (-0.72%)
SmarTrend Watching for Potential Pullback in Shares of Aimmune Therapeu After 2.51% Gain

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $21.30 to a high of $22.60. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high...

AIMT : 20.11 (-2.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AIMT with:

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

2nd Resistance Point 20.83
1st Resistance Point 20.47
Last Price 20.11
1st Support Level 19.80
2nd Support Level 19.49

See More

52-Week High 36.12
Fibonacci 61.8% 29.68
Fibonacci 50% 27.68
Fibonacci 38.2% 25.69
Last Price 20.11
52-Week Low 19.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar